Abstract
Because of the high rate of spontaneous remission, treatment of membranous nephropathy with prednisolone and chlorambucil is still controversial. The aim of this study was to give this therapy only to those patients at risk of developing renal insufficiency and to test the efficacy of a low-dose therapeutic regimen. Seventeen patients with more than 10 g protein excretion per day (mean 16.9) and/or a deterioration in renal function (mean serum creatinine, 162 μmol/l) were included. Serum total protein, serum lipids, proteinuria, serum creatinine, and blood pressure were measured, along with the diuretic and antihypertensive medication. The observation time before the start of treatment was 27 ± 27 months. Steroids were given during months 1, 3, and 5 (methylprednisolone 3 × 500 mg intravenously) prednisolone 0.5 mg/kgBW daily per os for 1 week, then tapered by 0.1 mg/kg BW/week for 1 month. Chlorambucil was given during months 2, 4, and 6 at a dose of 0.12 mg/kgBW daily. At the end of treatment proteinuria had significantly decreased (mean of all patients, 7.8 ± 1.4 g/d) in all patients. Six months after the end of treatment proteinuria was significantly lower than at baseline in 14 of 17 patients. Hypoproteinemia and hyperlipidemia had improved; diuretic and antihypertensive medication were reduced. Elevated serum creatinine decreased in 7 of 9 patients (pretreatment, 227 ± 39 μmol/1; 6 months, 176 ± 28 μmol/l). Nonresponders with respect to serum creatinine responded with respect to proteinuria. Regarding adverse effects, two patients complained of dyspepsia while taking steroids; during chlorambucil treatment two patients experienced nausea and lack of appetite, and one developed leukopenia (1600/μl). Chlorambucil was stopped and cell counts normalized 2 weeks later. We conclude that low-dose prednisolone/chlorambucil is both safe and efficient in the majority of patients with severe membranous nephropathy.
Similar content being viewed by others
Abbreviations
- MGN:
-
membranous glomerulonephritis
References
Bolton WK, Atuk NO, Sturgill BC, Westervelt FB (1977) Therapy of the idiopathic nephrotic syndrome with alternate day steroids. Am J Med 62:60–70
Cameron JS (1992) Membranous nephropathy — still a treatment dilemma (editorial; comment). N Engl J Med 327:638–639
Cameron JS, Healy MJ, Adu D (1990) The Medical Research Council trial of short-term high-dose alternate day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. The MRC Glomerulonephritis Working Party (comments). Q J Med 74:133–156
Cattran DC (1991) Current status of cyclosporin A in the treatment of membranous, IgA and membranoproliferative glomerulonephritis. Clin Nephrol 35:7–15
Cattran DC, Delmore T, Roscoe J, Cole E, Cardella C, Charron R, Ritchie S (1989) A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy. N Engl J Med 320:210–215
Ehrenreich J, Churg J (1968) Pathology of membranous nephropathy. Pathol Ann 3:145–151
Davison AM, Kerr DNS, Ogg CS, Wilkinson RW (1984) The natural history of renal function in untreated idiopathic membranous glomerulonephritis in adults. Clin Nephrol 22:61–67
Donadio JV, Torres VE, Velosa JA (1988) Idiopathic membranous nephropathy: the natural history of untreated patients. Kidney Int 33:708–715
Jacobs C, Brunner FP, Chantler C (1977) Combined report on regular dialysis and transplantation in Europe, VII, 1976. Proc Eur Dial Transplant Assoc 14:3–69
Lagrue G, Bernard D, Bariety JD, Druet P, Guenel J (1975) Traitement par le chlorambucil et l'azathioprine dans les glomérulonéphrites primitives: résultats d'une étude “con-ntrôlee”. J Urol Nephrol 81:655–672
Lewes EJ (1993) Idiopathic membranous nephropathy —to treat or not to treat? (editorial). N Engl J Med 329:127–129
Mathieson PW, Turner AN, Maidment CG, Evans DJ, Rees AJ (1988) Prednisolone and chlorambucil treatment in idiopathic membranous nephropathy with deteriorating renal function. Lancet 11:869–872
Murphy BF, McDonald I, Fairley KF, Kincaid SP (1992) Randomized controlled trial of cyclophosphamide, warfarin and dipyridamole in idiopathic membranous glomerulonephritis. Clin Nephrol 37:229–234
Pei Y, Cattran D, Greenwood C (1992) Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int 42:960–966
Pierides AM, Malasit P, Morley AR, Wilkinson R, Uldall PR, Kerr DN (1977) Idiopathic membranous nephropathy. Q J Med 46:163–177
Ponticelli C, Passerini P (1991) Conventional treatment of idiopathic nephrotic syndrome and membranous nephropathy in adults. Clin Nephrol 35:21–26
Ponticelli C, Zucchelli P, Passerine P, Cagnoli L, Cesana B, Pozzi C, Pasquali S, Imbasciati E, Grassi C, Redaelli B, et al (1989) A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 320:8–13
Ponticelli C, Zucchelli P, Passerini P, Cesana B (1992) Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian Idiopathic Membranous Nephropathy Treatment Study Group (comments). N Engl J Med 327:599–603
Schieppati A, Mosconi L, Perna A, Mecca G, Bertani T, Garattini S, Remuzzi G (1993) Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 329:85–89
Suki WN, Chavez A (1981) Membranous nephropathy: response to steroids and immunosuppression. Am J Nephrol 1:11–16
Wehrmann M, Bohle A, Bogenschutz O, Eissele R, Freislederer A, Ohlschlegel C, Schumm G, Batz C, Gartner HV (1989) Long-term prognosis of chronic idiopathic membranous glomerulonephritis. An analysis of 334 cases with particular regard to tubulo-interstitial changes. Clin Nephrol 31:67–76
West ML, Jindal KK, Bear RA, Goldstein MB (1987) A controlled trial of cyclophosphamide in patients with membranous glomerulonephritis. Kidney Int 32:579–584
Author information
Authors and Affiliations
Additional information
Correspondence to: R. Brunkhorst
Rights and permissions
About this article
Cite this article
Brunkhorst, R., Wrenger, E. & Koch, K.M. Low-dose prednisolone/chlorambucil therapy in patients with severe membranous glomerulonephritis. Clin Investig 72, 277–282 (1994). https://doi.org/10.1007/BF00180040
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00180040